Editorial: Selectivity in beta-adrenergic responses: clinical implications.
D000273:Adipose Tissue / Q000294:innervation; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000420:Albuterol / Q000494:pharmacology; D001980:Bronchi / Q000294:innervation; D002078:Butoxamine / Q000494:pharmacology; D005260:Female; D006321:Heart / Q000294:innervation; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008053:Lipid Mobilization; D008099:Liver / Q000294:innervation; D008112:Liver Glycogen / Q000378:metabolism; D008297:Male; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000294:innervation; D009132:Muscles / Q000294:innervation; D009928:Organ Specificity; D011217:Practolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic; D014599:Uterus / Q000294:innervation; D014666:Vasomotor System / Q000502:physiology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D008112:Liver Glycogen; D011941:Receptors, Adrenergic; D002078:Butoxamine; D011433:Propranolol; D007545:Isoproterenol; D000420:Albuterol; D011217:Practolol